PTH Serum Levels and Mortality Risk among Incident Hemodialysis Patients

Detalhes bibliográficos
Autor(a) principal: Roldão,Marisa
Data de Publicação: 2022
Outros Autores: Escoli,Rachele, Gonçalves,Hernâni, Sofia,Flora, Lopes,Karina, Santos,Paulo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692022000300156
Resumo: ABSTRACT Introduction: Chronic kidney disease (CKD)-mineral and bone disorder (MBD) is a major complication in hemodialysis (HD) patients. Serum intact parathyroid hormone (iPTH) has been associated with prognosis in these patients, however, the optimal range to reduce mortality remains unknown. Methods: We conducted a retrospective study of incident HD patients, who were categorized into 4 groups according to iPTH serum level: <150 pg/mL, 150-300 pg/mL, 301-600 pg/mL and >600 pg/mL. All-cause and cardiovascular mortality over a mean follow-up of 3 years was assessed using standard survival methods. Results: One hundred and forty-nine patients were included. Patients with low iPTH presented low serum albumin, phosphorus, and bonespecific alkaline phosphatase (BAP), increased c-reactive protein (CRP) and higher serum bicarbonate (p<0.05). Those with iPTH <150 pg/mL had an increased risk of all-cause and cardiovascular mortality, when compared to those with iPTH 301-600 pg/mL (HR: 0.59; 95% CI: 0.36-0.96; p=0.035) and iPTH >600 pg/mL (HR: 0.39; 95% CI: 0.20-0.78; p=0.008), even after adjusting for potential confounding factors as age, albumin, and comorbidities (diabetes, congestive heart failure (CHF), and hypertension). Discussion: PTH levels were associated with all-cause and cardiovascular mortality risk in our cohort of incident HD patients. Our results suggest that patients with low iPTH at HD initiation had an increased mortality risk, which may reflect a frail group of patients with anorexia, sarcopenia, malnutrition, and inflammation.
id RCAP_5dc4f68b23bc0e9ade33a05902b1e889
oai_identifier_str oai:scielo:S0872-01692022000300156
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling PTH Serum Levels and Mortality Risk among Incident Hemodialysis PatientsChronic Kidney Disease-Mineral and Bone Disorder/etiologyParathyroid HormoneRenal Dialysis/adverse effectsABSTRACT Introduction: Chronic kidney disease (CKD)-mineral and bone disorder (MBD) is a major complication in hemodialysis (HD) patients. Serum intact parathyroid hormone (iPTH) has been associated with prognosis in these patients, however, the optimal range to reduce mortality remains unknown. Methods: We conducted a retrospective study of incident HD patients, who were categorized into 4 groups according to iPTH serum level: <150 pg/mL, 150-300 pg/mL, 301-600 pg/mL and >600 pg/mL. All-cause and cardiovascular mortality over a mean follow-up of 3 years was assessed using standard survival methods. Results: One hundred and forty-nine patients were included. Patients with low iPTH presented low serum albumin, phosphorus, and bonespecific alkaline phosphatase (BAP), increased c-reactive protein (CRP) and higher serum bicarbonate (p<0.05). Those with iPTH <150 pg/mL had an increased risk of all-cause and cardiovascular mortality, when compared to those with iPTH 301-600 pg/mL (HR: 0.59; 95% CI: 0.36-0.96; p=0.035) and iPTH >600 pg/mL (HR: 0.39; 95% CI: 0.20-0.78; p=0.008), even after adjusting for potential confounding factors as age, albumin, and comorbidities (diabetes, congestive heart failure (CHF), and hypertension). Discussion: PTH levels were associated with all-cause and cardiovascular mortality risk in our cohort of incident HD patients. Our results suggest that patients with low iPTH at HD initiation had an increased mortality risk, which may reflect a frail group of patients with anorexia, sarcopenia, malnutrition, and inflammation.Sociedade Portuguesa de Nefrologia2022-09-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692022000300156Portuguese Journal of Nephrology &amp; Hypertension v.36 n.3 2022reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692022000300156Roldão,MarisaEscoli,RacheleGonçalves,HernâniSofia,FloraLopes,KarinaSantos,Pauloinfo:eu-repo/semantics/openAccess2024-02-06T17:05:14Zoai:scielo:S0872-01692022000300156Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:19:08.133234Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv PTH Serum Levels and Mortality Risk among Incident Hemodialysis Patients
title PTH Serum Levels and Mortality Risk among Incident Hemodialysis Patients
spellingShingle PTH Serum Levels and Mortality Risk among Incident Hemodialysis Patients
Roldão,Marisa
Chronic Kidney Disease-Mineral and Bone Disorder/etiology
Parathyroid Hormone
Renal Dialysis/adverse effects
title_short PTH Serum Levels and Mortality Risk among Incident Hemodialysis Patients
title_full PTH Serum Levels and Mortality Risk among Incident Hemodialysis Patients
title_fullStr PTH Serum Levels and Mortality Risk among Incident Hemodialysis Patients
title_full_unstemmed PTH Serum Levels and Mortality Risk among Incident Hemodialysis Patients
title_sort PTH Serum Levels and Mortality Risk among Incident Hemodialysis Patients
author Roldão,Marisa
author_facet Roldão,Marisa
Escoli,Rachele
Gonçalves,Hernâni
Sofia,Flora
Lopes,Karina
Santos,Paulo
author_role author
author2 Escoli,Rachele
Gonçalves,Hernâni
Sofia,Flora
Lopes,Karina
Santos,Paulo
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Roldão,Marisa
Escoli,Rachele
Gonçalves,Hernâni
Sofia,Flora
Lopes,Karina
Santos,Paulo
dc.subject.por.fl_str_mv Chronic Kidney Disease-Mineral and Bone Disorder/etiology
Parathyroid Hormone
Renal Dialysis/adverse effects
topic Chronic Kidney Disease-Mineral and Bone Disorder/etiology
Parathyroid Hormone
Renal Dialysis/adverse effects
description ABSTRACT Introduction: Chronic kidney disease (CKD)-mineral and bone disorder (MBD) is a major complication in hemodialysis (HD) patients. Serum intact parathyroid hormone (iPTH) has been associated with prognosis in these patients, however, the optimal range to reduce mortality remains unknown. Methods: We conducted a retrospective study of incident HD patients, who were categorized into 4 groups according to iPTH serum level: <150 pg/mL, 150-300 pg/mL, 301-600 pg/mL and >600 pg/mL. All-cause and cardiovascular mortality over a mean follow-up of 3 years was assessed using standard survival methods. Results: One hundred and forty-nine patients were included. Patients with low iPTH presented low serum albumin, phosphorus, and bonespecific alkaline phosphatase (BAP), increased c-reactive protein (CRP) and higher serum bicarbonate (p<0.05). Those with iPTH <150 pg/mL had an increased risk of all-cause and cardiovascular mortality, when compared to those with iPTH 301-600 pg/mL (HR: 0.59; 95% CI: 0.36-0.96; p=0.035) and iPTH >600 pg/mL (HR: 0.39; 95% CI: 0.20-0.78; p=0.008), even after adjusting for potential confounding factors as age, albumin, and comorbidities (diabetes, congestive heart failure (CHF), and hypertension). Discussion: PTH levels were associated with all-cause and cardiovascular mortality risk in our cohort of incident HD patients. Our results suggest that patients with low iPTH at HD initiation had an increased mortality risk, which may reflect a frail group of patients with anorexia, sarcopenia, malnutrition, and inflammation.
publishDate 2022
dc.date.none.fl_str_mv 2022-09-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692022000300156
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692022000300156
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692022000300156
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Nefrologia
publisher.none.fl_str_mv Sociedade Portuguesa de Nefrologia
dc.source.none.fl_str_mv Portuguese Journal of Nephrology &amp; Hypertension v.36 n.3 2022
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137280852492288